Poster
10
(#10) Real-world Impact of Transitioning from Oral or Once-monthly Injectable Aripiprazole to a 2-Month Ready-To-Use Aripiprazole Formulation on Adherence and Healthcare Utilization in US Adults Diagnosed with Schizophrenia
Psych Congress 2025
Background
Oral antipsychotics (OAPs) are commonly used to manage schizophrenia but are often associated with nonadherence, leading to increased healthcare resource utilization (HCRU). Long-acting injectables, including aripiprazole 2-Month Ready-To-Use (Ari 2MRTU), may improve adherence and reduce HCRU burden.
Objective
Assess patient characteristics, medication adherence, and HCRU among patients diagnosed with schizophrenia who transitioned from oral aripiprazole or aripiprazole once-monthly (AOM) to Ari 2MRTU, using a pre-post design.
Methods
This retrospective, non-interventional study used the Kythera Labs closed claims database (April 2022-March 2025) to identify commercially and Medicaid-insured US adults (≥18 years) diagnosed with schizophrenia who transitioned from oral aripiprazole or AOM to Ari 2MRTU. The Ari 2MRTU transition date was defined as the index date. Continuous enrollment for 12 months pre- and 6 months post-index was required. Adherence and HCRU were examined for 6 months pre- and post-index.
Results
Among patients transitioning from oral aripiprazole to Ari 2MRTU (n=153), adherence improved post-index (Proportion of Days Covered: [PDC]): 0.61 to 0.74; Medication Possession Ratio: [(MPR]): 0.69 to 0.86, p.001). All-cause hospitalizations declined (0.67 to 0.28, p=.01); length of stay (LOS) decreased (2.6 to 1.1 days, p=.008). Schizophrenia-related LOS dropped from 0.9 to 0.2 days (p=.03); outpatient services utilization declined (54.9% to 36.0%, p=.01). Among those who transitioned from AOM to Ari 2MRTU (n=526), adherence improved (PDC: 0.62 to 0.86; MPR: 0.67 to 0.92, both p.001); all-cause LOS declined (1.1 to 0.6 days, p=.04).
Conclusion
Transitioning to Ari 2MRTU significantly improved adherence and reduced HCRU, supporting its value in managing schizophrenia.
Short Description: This study examined the pre post impact on adherence and health care resource utilization among patients living with schizophrenia who are transitioned to aripiprazole 2-Month Ready-To-Use formulation from oral aripiprazole or aripiprazole once-monthly formulation.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development and Commercialization, H. Lundbeck A/S
Oral antipsychotics (OAPs) are commonly used to manage schizophrenia but are often associated with nonadherence, leading to increased healthcare resource utilization (HCRU). Long-acting injectables, including aripiprazole 2-Month Ready-To-Use (Ari 2MRTU), may improve adherence and reduce HCRU burden.
Objective
Assess patient characteristics, medication adherence, and HCRU among patients diagnosed with schizophrenia who transitioned from oral aripiprazole or aripiprazole once-monthly (AOM) to Ari 2MRTU, using a pre-post design.
Methods
This retrospective, non-interventional study used the Kythera Labs closed claims database (April 2022-March 2025) to identify commercially and Medicaid-insured US adults (≥18 years) diagnosed with schizophrenia who transitioned from oral aripiprazole or AOM to Ari 2MRTU. The Ari 2MRTU transition date was defined as the index date. Continuous enrollment for 12 months pre- and 6 months post-index was required. Adherence and HCRU were examined for 6 months pre- and post-index.
Results
Among patients transitioning from oral aripiprazole to Ari 2MRTU (n=153), adherence improved post-index (Proportion of Days Covered: [PDC]): 0.61 to 0.74; Medication Possession Ratio: [(MPR]): 0.69 to 0.86, p.001). All-cause hospitalizations declined (0.67 to 0.28, p=.01); length of stay (LOS) decreased (2.6 to 1.1 days, p=.008). Schizophrenia-related LOS dropped from 0.9 to 0.2 days (p=.03); outpatient services utilization declined (54.9% to 36.0%, p=.01). Among those who transitioned from AOM to Ari 2MRTU (n=526), adherence improved (PDC: 0.62 to 0.86; MPR: 0.67 to 0.92, both p.001); all-cause LOS declined (1.1 to 0.6 days, p=.04).
Conclusion
Transitioning to Ari 2MRTU significantly improved adherence and reduced HCRU, supporting its value in managing schizophrenia.
Short Description: This study examined the pre post impact on adherence and health care resource utilization among patients living with schizophrenia who are transitioned to aripiprazole 2-Month Ready-To-Use formulation from oral aripiprazole or aripiprazole once-monthly formulation.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development and Commercialization, H. Lundbeck A/S
